Didier TronoAfter obtaining an M.D. from the University of Geneva and completing a clinical training in pathology, internal medicine and infectious diseases in Geneva and at Massachusetts General Hospital in Boston, Didier Trono embarked in a scientific career at the Whitehead Institute for Biomedical Research of MIT. In 1990, he joined the faculty of the Salk Institute for Biological Studies to launch a center for AIDS research. He moved back to Europe seven years later, before taking the reins of the newly created EPFL School of Life Sciences, which he directed from 2004 to 2012. He is now actively engaged in the efforts of Switzerland to integrate new technologies in the fields of precision medicine and personalized health.
Johan AuwerxJohan Auwerx is Professor at the École Polytechnique Fédérale in Lausanne, Switzerland, where he occupies the Nestle Chair in Energy Metabolism. Dr. Auwerx has been using molecular physiology and systems genetics to understand metabolism in health, aging and disease. Much of his work focused on understanding how diet, exercise and hormones control metabolism through changing the expression of genes by altering the activity of transcription factors and their associated cofactors. His work was instrumental for the development of agonists of nuclear receptors - a particular class of transcription factors - into drugs, which now are used to treat high blood lipid levels, fatty liver, and type 2 diabetes. Dr. Auwerx was amongst the first to recognize that transcriptional cofactors, which fine-tune the activity of transcription factors, act as energy sensors/effectors that influence metabolic homeostasis. His research validated these cofactors as novel targets to treat metabolic diseases, and spurred the clinical use of natural compounds, such as resveratrol, as modulators of these cofactor pathways.
Johan Auwerx was elected as a member of EMBO in 2003 and is the recipient of a dozen of international scientific prizes, including the Danone International Nutrition Award, the Oskar Minkowski Prize, and the Morgagni Gold Medal. His work is highly cited by his peers with a h-factor of over 100. He is an editorial board member of several journals, including Cell Metabolism, Molecular Systems Biology, The EMBO Journal, Journal of Cell Biology, Cell, and Science. Dr. Auwerx co-founded a handful of biotech companies, including Carex, PhytoDia, and most recently Mitobridge, and has served on several scientific advisory boards.
Dr. Auwerx received both his MD and PhD in Molecular Endocrinology at the Katholieke Universiteit in Leuven, Belgium. He was a post-doctoral research fellow in the Departments of Medicine and Genetics of the University of Washington in Seattle.
Elisa OricchioExpertise
Cancer geneticsMouse modelsTherapyStem cellsLymphoma
Teaching & PhD PhD Students Vamsi Krishna Polavarapu, Asli Ece Kasapoglu, Konstantina Georgakopoulou, Eleni Balli Past EPFL PhD Students Maria Christine Donaldson, Elena Battistello, Daniel Pereira Duarte, Frédérica Schyrr, Ruxandra-Andreea Lambuta, Aaron Simone Petruzzella, Jixing Zhong, Justine Epiney Courses Cancer biology I BIO-471 The course covers in detail molecular mechanisms of cancer development with emphasis on cell
Georges WagnièresGeorges Wagnières received his diploma degree (MSc) in physics from the University of Lausanne, Switzerland, in 1986. He obtained his doctorate in science (PhD) in physics (Biomedical optics) from the Swiss Federal Institute of Technology at Lausanne (EPFL) in 1992 and did a postdoctoral work in the Wellman Laboratories of Photomedicine (Harvard Medical School), Boston, USA, from 1993 to 1994. He also obtained a Master degree in Management of Technology delivered by the Ecole des Hautes Etudes Commerciales (HEC) of Lausanne University and the EPFL in 2001. Georges Wagnières manages a research group active in the fields of: - Detection of early superficial cancers by fluorescence imaging. - Characterization of early superficial cancers by high magnification narrow band imaging. - In vivo and in vitro measurement of the vascular and tissular oxygen concentration by time-resolved luminescence spectroscopy and imaging. - Preclinical and clinical study of new photosensitizers for photodynamic therapy (PDT). - Treatment of neurodegenerative conditions (Alzheimer, Parkinson's diseases) by photobiomodulation. - Preclinical and clinical photodynamic therapy of inflammatory bowel diseases and atheroscerotic plaque. - Improvement of the selective vascular extravasation of chemotherapeutic agents by PDT. - Monitoring the light dosimetry during PDT by fluorescence spectroscopy and imaging. - Monitoring laser treatments of the retina by reflectance imaging. - Light dosimetry and tissue optical spectroscopy. - Radiometry. - Development of light delivery systems for biomedical applications. Georges Wagnières is also co-founder and was chairman of one spin-off companies: - Medlight SA, founded in July 1997, which develops, produces and commercializes light distributors for photodynamic therapy. Georges Wagnières has currently authored more than 235 papers (more than 150 in international journals with review board) and is inventor of 18 patents. He supervised 12 PhD students up to now, and currently teaches biomedical optics and photomedicine in master programs and doctoral schools. In addition, he gives the course entitled "Physique Générale I" to biology first year students registered to the Biology School of the Lausanne's University. MAIN PUBLICATIONS Please visit: https://www.epfl.ch/labs/lifmet/wagnieres/publications/ Pascal FrossardTeaching & PhD PhD Students Yiming Qin, Alba Carballo Castro, Elisa Messori, Ke Wang, Sevda Ögüt, Tuna Alikasifoglu, William Cappelletti, Manuel Madeira, Mahdi Amiri, Ortal Yona Senouf, Vasiliki Rizou, Cem Bilaloglu, Abdellah Rahmani, Amel Abdelraheem, Jérémy Jean Philippe Baffou, Adam Hazimeh, Vincent Jung, Yike Zhao Past EPFL PhD Students Dan Jurca, Jean-Paul Wagner, Ivana Radulovic, Ivana Tosic, Effrosyni Kokiopoulou, Zafer Arican, Vijayaraghavan Thirumalai, Tamara Tosic, Eirina Bourtsoulatze, Elif Vur
Christian HeinisTeaching & PhD PhD Students Thomas Julien Denis Emel, Alessandro Scapozza, Nathan Moïse De Sadeleer, Florian Handel, Hugo André Clerc, Frédéric Brantschen, Grégoire Menoud, Ines Michrafy, Jonathan Schmitt, Laura Elena Massaad Past EPFL PhD Students Jeremy Touati, Shiyu Chen, Sophie Venet-Bonnot, Lisa Pollaro, Inmaculada Rentero Rebollo, Philippe Diderich, Charlotte Urech-Varenne, Silvia Bellotto, Davide Bertoldo, Alessandro Zorzi, Camille Villequey, Jonas Alfred Karl Wilbs, Grigory Karateev, Vanessa Carle
Horst PickTeaching & PhD PhD Students Vivek Prakash, Yang Wang Past EPFL PhD Students as codirector Olivia Baud, Thamani Dahoun, Enio Daniel Zanchetta Courses Biotechnology lab (for CGC) ChE-433 This laboratory-training course is designed to give students a comprehensive insight into laboratory research techniques in the field of biotechnology and pharmaceutical biotechnology with practices employed in the industry. Accompanying lectures provide the theoretical background. Chemosensory receptors:
Myriam BrikiExpertise
PharmacometricsTherapeutic drug monitoringAnalytical chemistry
Myriam Briki obtained her BSc from the University of Lausanne after spending her final year at Uppsala University (Sweden), where she was able to focus mainly on toxicological sciences. As a result, she chose to specialize in pharmacology and toxicology during her MSc back in Lausanne. She is now doing her PhD under the direction of Prof. Sandro Carrara (EPFL) and Dr. Monia Guidi (CHUV).Her project, carried out at the University Hospit
Show more